重组水疱性口炎病毒苏丹型埃博拉病毒疫苗在美国成人中的安全性和免疫原性：单盲、首次人体、剂量递增1期临床试验
Safety and immunogenicity of a recombinant vesicular stomatitis virus-based Sudan virus vaccine in adults in the USA: a single-blind, first-in-human, dose-escalation phase 1 clinical trial
苏丹病毒（SUDV）引起致命出血热，亟需疫苗。这项首次人体、单盲、安慰剂对照、剂量递增1期试验在美国两个中心招募36名健康成人，单次肌注rVSVΔG-SEBOV-GP疫苗（2×10^6、2×10^7或2×10^8 PFU）或安慰剂。结果显示疫苗在所有剂量下耐受良好，多数不良事件为轻中度局部疼痛和全身反应，严重反应少见且短暂。抗体应答在29天时出现，所有剂量组相似，并维持至6个月；67%疫苗接种者检测到中和活性。该疫苗值得进一步开发用于预防苏丹病毒病。
为什么推荐给您：苏丹病毒疫苗首次人体试验，显示安全性和免疫原性，属新模态早期阳性结果。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
BACKGROUND: A vaccine is needed to prevent Sudan virus (SUDV) disease (SVD), a haemorrhagic fever. We report a first-in-human clinical trial evaluating the safety and immunogenicity of a recombinant vesicular stomatitis virus (rVSV) vaccine expressing the SUDV envelope glycoprotein (rVSVΔG-SEBOV-GP).
METHODS: In this single-blind, placebo-controlled, dose-escalation phase 1 trial, adults (18-50 years) in good general health and without previous exposure to VSV-vectored vaccines or any haemorrhagic fever, were enrolled at two clinical research sites in Texas, USA. Participants received a single intramuscular dose of rVSVΔG-SEBOV-GP at 2 × 10^6, 2 × 10^7, or 2 × 10^8 plaque-forming units, or placebo. Dose groups were enrolled sequentially, from the lowest to the highest dose. In each dose group, the first two participants (sentinels) received the vaccine without randomisation; the remaining were randomised (4:1 vaccine-to-placebo ratio, for a final vaccine-to-placebo ratio of 5:1). Only participants were masked. Primary outcomes, assessed on all participants, were safety and tolerability assessments, based on local and systemic reactions within 14 days, and vaccine-related serious adverse events and adverse events of special interest for the entire trial. Secondary outcome was the evaluation of humoral immunity, assessed by anti-SUDV-GP IgG and serum neutralising activity against SUDV-GP at baseline and 28, 84, and 168 days after vaccination. This study (now completed) is registered at ClinicalTrials.gov (NCT05724472).
FINDINGS: Between June 19, 2023, and July 21, 2023, 36 participants (20 [56%] women; median age 37 years [IQR=12·2]) were enrolled and received a single intramuscular injection of vaccine (n=10 per dose group) or placebo (n=6); all vaccine recipients completed 6 months of follow-up. 31 (86%) of 36 (vaccine 26 [87%] of 30; placebo five [83%] of six) participants had solicited adverse events; the proportions were similar across all dose groups. Most participants (vaccine 22 [73%] of 30; placebo five [83%] of six) had local pain and tenderness, mild to moderate, but severe in one participant (2 × 10^8 plaque-forming units). Systemic reactions occurred in 25 (83%) of 30 vaccine recipients and four (67%) of six placebo recipients. Severe transient reactions were reported by one (17%) of six placebo recipients (joint pain) and four (13%) of 30 vaccine recipients (combinations of malaise, chills, myalgia, abdominal pain, headache, and nausea). Antibody responses, present by day 29 and beyond, were similar at all dosages, and maintained in all participants by month 6. By the end of the study, neutralising activity was detected in 20 (67%) of 30 vaccinees and correlated to binding IgG.
INTERPRETATION: rVSVΔG-SEBOV-GP was well tolerated and immunogenic at all the three doses studied. These findings support its further development for prevention of SVD.
FUNDING: Biomedical Advanced Research and Development Authority.